In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Xiyanping injection has anti-inflammatory and immune regulation effects. This study is a Randomized, Parallel Controlled Clinical Study to treat patients with COVID-19 infection.
The new coronavirus (COVID-19) [1] belongs to the new beta coronavirus. Current research
shows that it has 85% homology with bat SARS-like coronavirus (bat-SL-CoVZC45), but its
genetic characteristics are similar to SARSr-CoV. There is a clear difference from MERSr-COV.
Since December 2019, Wuhan City, Hubei Province has successively found multiple cases of
patients with pneumonia infected by a new type of coronavirus. With the spread of the
epidemic, as of 12:00 on February 12, 2020, a total of 44726 confirmed cases nationwide
(Hubei Province) 33,366 cases, accounting for 74.6%), with 1,114 deaths (1068 cases in Hubei
Province), and a mortality rate of 2.49% (3.20% in Hubei Province).
In view of the fact that there is currently no effective antiviral therapy, the prevention or
treatment of lung injury caused by COVID-19 can be an alternative target for current
treatment. Xiyanping injection has anti-inflammatory and immune regulation effects. In the
early clinical practice of treating severe H1N1, it was clinically concerned, and combined
with conventional treatment, and achieved good results.
Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection
Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
Drug: Lopinavir/ritonavir treatment
Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
Inclusion Criteria:
1. Aged >=18 years;
2. Novel coronavirus pneumonia patients diagnosed by pathogenic testing;
3. The patient himself participated in the study voluntarily, agreed and signed the
informed consent.
Exclusion Criteria:
1. Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia;
2. Severe primary diseases that affect survival, including: uncontrolled malignant
tumors, hematological diseases, and HIV that have not been metastasized in multiple
places;
3. Obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, and
allergic alveolitis caused by lung tumors;
4. Women who are breastfeeding or pregnant;
5. Those who are known to be allergic to the ingredients contained in the research
medication, or patients with allergies;
6. Those who have continued to use immunosuppressive agents or organ transplants in the
past 6 months;
7. Patients who have participated in other drug clinical trials within 3 months before
the screening test;
8. The investigator judges that he or she cannot complete or should not participate in
the study (expected death within 48 hours, and the patient refuses active treatment)